Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma.
Identifieur interne : 000598 ( Main/Exploration ); précédent : 000597; suivant : 000599Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma.
Auteurs : RBID : pubmed:23453421English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Antibodies, Monoclonal (diagnostic use), Antigens, Neoplasm (immunology), Carbonic Anhydrases (immunology), Carcinoma, Renal Cell (immunology), Carcinoma, Renal Cell (radionuclide imaging), Female, Humans, Indium Radioisotopes (diagnostic use), Kidney Neoplasms (immunology), Kidney Neoplasms (radionuclide imaging), Male, Middle Aged, Radiopharmaceuticals (diagnostic use), Tomography, Emission-Computed, Single-Photon, Tumor Markers, Biological (immunology).
- MESH :
- chemical , diagnostic use : Antibodies, Monoclonal, Indium Radioisotopes, Radiopharmaceuticals.
- chemical , immunology : Antigens, Neoplasm, Carbonic Anhydrases, Tumor Markers, Biological.
- immunology : Carcinoma, Renal Cell, Kidney Neoplasms.
- radionuclide imaging : Carcinoma, Renal Cell, Kidney Neoplasms.
- Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Tomography, Emission-Computed, Single-Photon.
Abstract
Improved and more frequent radiologic evaluation has resulted in increased identification of renal masses of unknown origin, which frequently pose a diagnostic dilemma for urologists.
DOI: 10.1016/j.eururo.2013.02.022
PubMed: 23453421
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma.</title><author><name sortKey="Muselaers, Constantijn H J" uniqKey="Muselaers C">Constantijn H J Muselaers</name><affiliation wicri:level="1"><nlm:affiliation>Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. s.muselaers@uro.umcn.nl</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen</wicri:regionArea></affiliation></author><author><name sortKey="Boerman, Otto C" uniqKey="Boerman O">Otto C Boerman</name></author><author><name sortKey="Oosterwijk, Egbert" uniqKey="Oosterwijk E">Egbert Oosterwijk</name></author><author><name sortKey="Langenhuijsen, Johannes F" uniqKey="Langenhuijsen J">Johannes F Langenhuijsen</name></author><author><name sortKey="Oyen, Wim J G" uniqKey="Oyen W">Wim J G Oyen</name></author><author><name sortKey="Mulders, Peter F A" uniqKey="Mulders P">Peter F A Mulders</name></author></titleStmt><publicationStmt><date when="2013">2013</date><idno type="doi">10.1016/j.eururo.2013.02.022</idno><idno type="RBID">pubmed:23453421</idno><idno type="pmid">23453421</idno><idno type="wicri:Area/Main/Corpus">000770</idno><idno type="wicri:Area/Main/Curation">000770</idno><idno type="wicri:Area/Main/Exploration">000598</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Antibodies, Monoclonal (diagnostic use)</term><term>Antigens, Neoplasm (immunology)</term><term>Carbonic Anhydrases (immunology)</term><term>Carcinoma, Renal Cell (immunology)</term><term>Carcinoma, Renal Cell (radionuclide imaging)</term><term>Female</term><term>Humans</term><term>Indium Radioisotopes (diagnostic use)</term><term>Kidney Neoplasms (immunology)</term><term>Kidney Neoplasms (radionuclide imaging)</term><term>Male</term><term>Middle Aged</term><term>Radiopharmaceuticals (diagnostic use)</term><term>Tomography, Emission-Computed, Single-Photon</term><term>Tumor Markers, Biological (immunology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Indium Radioisotopes</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antigens, Neoplasm</term><term>Carbonic Anhydrases</term><term>Tumor Markers, Biological</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Carcinoma, Renal Cell</term><term>Kidney Neoplasms</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Carcinoma, Renal Cell</term><term>Kidney Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Tomography, Emission-Computed, Single-Photon</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Improved and more frequent radiologic evaluation has resulted in increased identification of renal masses of unknown origin, which frequently pose a diagnostic dilemma for urologists.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">23453421</PMID><DateCreated><Year>2013</Year><Month>04</Month><Day>23</Day></DateCreated><DateCompleted><Year>2013</Year><Month>11</Month><Day>12</Day></DateCompleted><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-7560</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><Issue>6</Issue><PubDate><Year>2013</Year><Month>Jun</Month></PubDate></JournalIssue><Title>European urology</Title><ISOAbbreviation>Eur. Urol.</ISOAbbreviation></Journal><ArticleTitle>Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma.</ArticleTitle><Pagination><MedlinePgn>1101-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eururo.2013.02.022</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0302-2838(13)00134-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Improved and more frequent radiologic evaluation has resulted in increased identification of renal masses of unknown origin, which frequently pose a diagnostic dilemma for urologists.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Carbonic anhydrase IX (CAIX) is an antigen ubiquitously expressed in clear cell renal cell carcinoma (ccRCC). The specific and high level of expression in ccRCC makes CAIX an excellent target for imaging ccRCC lesions. We present our experience with immuno-single-photon emission computed tomography (immunoSPECT) imaging with the indium-111 ((111)In)-labeled anti-CAIX antibody girentuximab in patients presenting with either a primary renal tumor or a history of ccRCC and lesions suspect for metastases during follow-up.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Twenty-nine patients received 100-200 MBq (111)In-labeled girentuximab. Whole-body and single photon emission computed tomography (SPECT) images were acquired after 4-7 d.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">Injection with (111)In-girentuximab and image acquisition after 4-7 d.</AbstractText><AbstractText Label="OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS" NlmCategory="METHODS">Accuracy of (111)In-girentuximab immunoSPECT.</AbstractText><AbstractText Label="RESULTS AND LIMITATIONS" NlmCategory="CONCLUSIONS">Distinct uptake of (111)In-girentuximab was seen in 16 of 22 patients presenting with a renal mass. All renal masses proven to be ccRCC after resection (n=15) were detected with (111)In-girentuximab. Suspect lesions of six patients showed no uptake of (111)In-girentuximab. In these patients, ccRCC was not found, nor progression occurred. Seven patients with a history of ccRCC and possible metastatic lesions on follow-up computed tomography scans were imaged with (111)In-girentuximab. In four of these patients, the lesions showed preferential uptake of (111)In-girentuximab and local or systemic treatment was initiated. In three other cases, no (111)In-girentuximab targeting was seen. During follow-up of these three patients, one showed progression, for which systemic treatment was started. In the two other patients, no progression occurred, suggesting a benign nature.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">(111)In-girentuximab immunoSPECT can be used to detect ccRCC lesions in patients with a primary renal mass and to clarify the nature of lesions suspect for metastases in patients with a history of ccRCC.</AbstractText><CopyrightInformation>Copyright © 2013 European Association of Urology. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Muselaers</LastName><ForeName>Constantijn H J</ForeName><Initials>CH</Initials><Affiliation>Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. s.muselaers@uro.umcn.nl</Affiliation></Author><Author ValidYN="Y"><LastName>Boerman</LastName><ForeName>Otto C</ForeName><Initials>OC</Initials></Author><Author ValidYN="Y"><LastName>Oosterwijk</LastName><ForeName>Egbert</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Langenhuijsen</LastName><ForeName>Johannes F</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Oyen</LastName><ForeName>Wim J G</ForeName><Initials>WJ</Initials></Author><Author ValidYN="Y"><LastName>Mulders</LastName><ForeName>Peter F A</ForeName><Initials>PF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>02</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Eur Urol</MedlineTA><NlmUniqueID>7512719</NlmUniqueID><ISSNLinking>0302-2838</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Antigens, Neoplasm</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>G250 monoclonal antibody</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Indium Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Tumor Markers, Biological</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 4.2.1.1</RegistryNumber><NameOfSubstance>CA9 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 4.2.1.1</RegistryNumber><NameOfSubstance>Carbonic Anhydrases</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease">Clear-cell metastatic renal cell carcinoma</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Eur Urol. 2013 Oct;64(4):e83</RefSource><PMID Version="1">23859982</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Eur Urol. 2013 Oct;64(4):e82</RefSource><PMID Version="1">23849417</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName MajorTopicYN="Y">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Antigens, Neoplasm</DescriptorName><QualifierName MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Carbonic Anhydrases</DescriptorName><QualifierName MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Carcinoma, Renal Cell</DescriptorName><QualifierName MajorTopicYN="N">immunology</QualifierName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Indium Radioisotopes</DescriptorName><QualifierName MajorTopicYN="Y">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Kidney Neoplasms</DescriptorName><QualifierName MajorTopicYN="N">immunology</QualifierName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radiopharmaceuticals</DescriptorName><QualifierName MajorTopicYN="Y">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Tomography, Emission-Computed, Single-Photon</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Tumor Markers, Biological</DescriptorName><QualifierName MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>12</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>2</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2013</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pii">S0302-2838(13)00134-6</ArticleId><ArticleId IdType="doi">10.1016/j.eururo.2013.02.022</ArticleId><ArticleId IdType="pubmed">23453421</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000598 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000598 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:23453421
|texte= Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:23453421" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |